Multi-analyte analysis of cytokines that predict outcomes in patients with hepatocellular carcinoma treated with radiotherapy

Table 2 Univariate and multivariate analyses of clinical factors or cytokines for failure-free survival - overall survival

	Univariate		Multivariate
	P value	RR (95%CI)	P value	RR (95%CI)
Sex	0.580	1.276 (0.538-3.027)
Age	0.954	1.001 (0.970-1.033)
Stage	0.861	1.052 (0.600-1.844)
BCLC	0.224	1.252 (0.872-1.799)
Size	0.308	1.037 (0.967-1.113)
PVT	0.132	1.581 (0.871-2.871)
LN metastasis	0.867	1.092 (0.389-3.061)
Multiplicity	0.957	1.016 (0.561-1.841)
AFP	0.020	1.001 (1.000-1.002)	0.020	1.001 (1.000-1.002)
PIVKA-II	0.211	1.022 (0.988-1.056)
Pre-RT treatment	0.693	0.887 (0.487-1.608)
Baseline IL-1	0.262	0.979 (0.942-1.016)
Baseline IL-6	0.692	1.001 (0.996-1.007)
Baseline IL-8	0.770	1.000 (0.998-1.002)
Baseline IL-10	0.909	0.994 (0.890-1.109)
Baseline IL-12	0.449	1.014 (0.978-1.052)
Baseline TNF-α	0.573	0.984 (0.930-1.041)

Age, size, AFP, PIVKA-II, and baseline cytokine levels were analyzed as continuous variables using the Cox hazard ratio model. BCLC: Barcelona Clinic Liver Cancer; PVT: Portal vein thrombosis; LN: Lymph node; AFP: α-fetoprotein; PIVKA-II: Prothrombin induced by vitamin K absence-II; RT: Radiotherapy; IL: Interleukin; TNF: Tumor necrosis factor.